Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease

  • Authors:
    • Xiaohong Zhang
    • Ronghua Yu
    • Huilin Wang
    • Ruifeng Zheng
  • View Affiliations

  • Published online on: June 10, 2020     https://doi.org/10.3892/etm.2020.8872
  • Pages: 1789-1795
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to examine the effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease (AD). For this purpose, a total of 126 patients with AD admitted to Luoyang Central Hospital from January, 2018 to December, 2018 were enrolled. Patients were divided into different groups according to the treatment they selected. Patients treated with single‑agent donepezil were separated into a monotherapy group (n=56), and patients receiving donepezil plus rivastigmine were placed in the combination group (n=70). Before and after treatment, the cognitive functions, mental behavior and quality of life of the patients in the two groups were respectively evaluated by the Alzheimer's Disease Assessment Scale‑Cognitive Subscale (ADAS‑Cog), the Mini‑Mental State Examination (MMSE), the Blessed‑Roth Dementia Scale (BRDS) and the QOL‑AD. In addition, the serum bradykinin level was detected by enzyme‑linked immunosorbent assay. Following treatment, the MMSE score, BRDS, ADAS‑Cog and QOL‑AD scores were improved compared with those before treatment (P<0.05). However, following treatment, the 4 scores in the combination group were significantly higher than those in the monotherapy group (P<0.05). No significant differences were observed in the incidence of adverse reactions between the 2 groups (P>0.05). Following treatment, the bradykinin level in both groups was significantly decreased (P<0.05), although the decrease in the combination group was more significant than that in the monotherapy group (P<0.05). On the whole, the findings of the present study indicate that rivastigmine hydrogen tartrate used in combination with donepezil hydrochloride relieves the symptoms and improves the quality of life of patients with AD more effectively, which may be related to the reduction of the bradykinin level in these patients.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Zhang, X., Yu, R., Wang, H., & Zheng, R. (2020). Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease. Experimental and Therapeutic Medicine, 20, 1789-1795. https://doi.org/10.3892/etm.2020.8872
MLA
Zhang, X., Yu, R., Wang, H., Zheng, R."Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease". Experimental and Therapeutic Medicine 20.2 (2020): 1789-1795.
Chicago
Zhang, X., Yu, R., Wang, H., Zheng, R."Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease". Experimental and Therapeutic Medicine 20, no. 2 (2020): 1789-1795. https://doi.org/10.3892/etm.2020.8872